Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With AR. RinASol- Pilot Study (RinASol)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02729012
Recruitment Status : Completed
First Posted : April 6, 2016
Last Update Posted : January 12, 2017
Sponsor:
Information provided by (Responsible Party):
Stefania La Grutta, MD, Istituto per la Ricerca e l'Innovazione Biomedica

Brief Summary:

The main objective of RinASol project is to assess in patients with seasonal Allergic Rhinitis the effect of hypertonic saline solution NACL 3%+NAHCO3 vs the effect of standard saline solution on nasal inflammation by means of nasal cytology.

The secondary objective is the symptom score assessment by T5SS Questionnaire (Total Symptom Score 5)


Condition or disease Intervention/treatment Phase
Allergic Rhinitis Drug: hypertonic saline solution (NACL 3%+NAHCO3) Other: Saline Solution (NACL 0,9%) Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With Allergic Rhinitis. RinASol- Pilot Study (Allergic Rhinitis Solution)
Study Start Date : October 2015
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Case
Allergic Rhinitis Children treated with hypertonic saline solution (NACL 3%+NAHCO3)
Drug: hypertonic saline solution (NACL 3%+NAHCO3)
Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)

Placebo Comparator: Control
Allergic Rhinitis Children treated with saline solution (NACL 0,9%)
Other: Saline Solution (NACL 0,9%)
Treatment with nebulized Saline Solution (NACL 0,9%)




Primary Outcome Measures :
  1. Symptom score assessment [ Time Frame: 28 days ]
    The main objective is to evaluate the effect of hypertonic saline solution NACL 3%+NAHCO3 vs the effect of standard saline solution on the symptom score assessed by T5SS Questionnaire (Total Symptom Score 5)


Secondary Outcome Measures :
  1. Nasal cytology pattern [ Time Frame: 28 days ]
    The secondary objective is to evaluate the effect of hypertonic saline solution NACL 3%+NAHCO3 vs the effect of standard saline solution on nasal inflammation, in patients with seasonal Allergic Rhinitis, by means of nasal cytology.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 14 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical history of Allergic Rhinitis (for at least 1 year)
  • 6 years old ≤ children age ≤ 14 years old
  • Total Symptom Score 5: >5 in the last 4 days before screening. Exclusion Criteria
  • Signs of acute infections of upper and lower respiratory tract.
  • Metabolic, immunological, systemic diseases
  • Respiratory tract deformity
  • Systemic/Topical therapies with antibiotics or corticosteroids in the previous 30 days.
  • Active smoker.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02729012


Locations
Layout table for location information
Italy
Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council
Palermo, Sicily, Italy, 90146
Sponsors and Collaborators
Stefania La Grutta, MD
Investigators
Layout table for investigator information
Principal Investigator: Stefania La Grutta, MD IBIM,CNR, PALERMO, ITALY
Layout table for additonal information
Responsible Party: Stefania La Grutta, MD, Stefania La Grutta, MD. Senior Researcher. Coordinator of Pediatric Allergy and Asthma Research Group. Institute of Biomedicine and Molecular Immunology, IBIM, National Research Council of Palermo, Italy., Istituto per la Ricerca e l'Innovazione Biomedica
ClinicalTrials.gov Identifier: NCT02729012    
Other Study ID Numbers: -11/2014
First Posted: April 6, 2016    Key Record Dates
Last Update Posted: January 12, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Stefania La Grutta, MD, Istituto per la Ricerca e l'Innovazione Biomedica:
Children
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Inflammation
Pathologic Processes
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Pharmaceutical Solutions